Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - PharmiWeb.com (press release)

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS PharmiWeb.com (press release) Basel, August 25, 2016 - Novartis today announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the ... and more »

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - PharmiWeb.com (press release)
Read More